Elsevier Inc.

SHERPA: Unknown

People

  1. Abu-Rustum
    Abu-Rustum
  2. Chi
    Chi
  3. Lee
    Lee
  4. Giralt
    Giralt
  5. Mulhall
    Mulhall
  6. Perales
    Perales
  7. Sonoda
    Sonoda
  8. Leitao
    Leitao
  9. Yorke
    Yorke
  10. Wu
    Wu

Groups

  1. Department of Medicine (4608)
  2. Surgery (3547)
  3. Survivorship Research (2657)
  4. Solid Tumor Oncology Division (2651)
  5. Radiation Oncology, Department of (2122)
  6. GSK Faculty (1936)
  7. Center for Hematologic Malignancies (1671)
  8. Hematologic Malignancies, Division of (1608)
  9. Gynecology Disease Management Team (1426)
  10. Sloan Kettering Institute Faculty (1398)
Search Within
Formats
  1. Journal Article (7381)
  2. Meeting Abstract (4692)
  3. Review (615)
  4. Book Section (538)
  5. Editorial (250)
  6. Conference Paper (138)
  7. Correspondence (92)
  8. Guidelines (82)
  9. Research Letter (29)
  10. Miscellaneous (15)
  11. Book Whole (14)
Groups
  1. Department of Medicine (4608)
  2. Surgery (3547)
  3. Survivorship Research (2657)
  4. Solid Tumor Oncology Division (2651)
  5. Radiation Oncology, Department of (2122)
  6. GSK Faculty (1936)

More Groups

People
  1. Nadeem Abu-Rustum (464)
  2. Dennis Chi (420)
  3. Nancy Lee (409)
  4. Michael Zelefsky (401)
  5. Sergio Giralt (384)
  6. John Mulhall (377)

More People

Years
  1. 2025 (243)
  2. 2024 (783)
  3. 2023 (760)
  4. 2022 (794)
  5. 2021 (723)
  6. 2020 (714)

More Years

Publications
  1. International Journal of Radiation Oncology, Biology, Physics (2611)
  2. Gynecologic Oncology (1197)
  3. Journal of Thoracic Oncology (967)
  4. Biology of Blood and Marrow Transplantation (815)
  5. European Journal of Cancer (525)
  6. Journal of Sexual Medicine (435)

More Publications

Results (13846)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Comparative effectiveness of teclistamab versus real-world physician's choice of therapy for patients with triple-class exposed relapsed/refractory multiple myeloma
    Meeting Abstract

    Krishnan, A.; Nooka, A.; Chari, A.; Garfall, A.; Martin, T.; Nair, S.; Lin, X.; Qi, K. Q.; Londhe, A.; Pei, L.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Matching-adjusted indirect treatment comparison (MAIC) of teclistamab vs approved therapies for the treatment of patients with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM)
    Meeting Abstract

    Moreau, P.; Usmani, S.; van de Donk, N. W. C. J.; Garfall, A.; Delforge, M.; Oriol, A.; Nooka, A.; Rosiñol, L.; Bahlis, N.; Rodriguez-Otero, P.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • A pilot plant based dietary intervention in MGUS and SMM is feasible and associated with reduction in insulin and leptin levels
    Meeting Abstract

    Shah, U.; Castro, F.; Anuraj, A.; Blaslov, J.; Adintori, P.; Derkach, A.; Pollak, M.; Maclachlan, K.; Mailankody, S.; Korde, N.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Bone remineralization of lytic lesions in newly diagnosed multiple myeloma (NDMM) patients treated with carfilzomib, lenalidomide, dexamethasone +/- daratumumab induction regimen
    Meeting Abstract

    Meseha, M.; Abusamra, M.; Farooki, A.; Derkach, A.; Maclachlan, K.; Hultcrantz, M.; Hassoun, H.; Shah, U.; Lu, S.; Mailankody, S.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Network topology analysis reveals unique multiple myeloma genomic subtypes and potential new therapeutic targets
    Meeting Abstract

    Simhal, A.; Maclachlan, K.; Elkin, R.; Zhu, J.; Usmani, S.; Deasy, J. O.; Oh, J. H.; Tannenbaum, A.
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Evaluating serum free light chain ratio as a biomarker for multiple myeloma
    Meeting Abstract

    Akhlaghi, T.; Maclachlan, K.; Korde, N.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Lu, S.; Patel, D.; Shah, U.; Tan, C.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • African American patients with smoldering multiple myeloma may have a lower risk of progression compared to white patients
    Meeting Abstract

    Akhlaghi, T.; Maclachlan, K.; Korde, N.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Lu, S.; Patel, D.; Shah, U.; Tan, C.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Prognostic utility of the evolving biomarker-based progression model (e-model) for smoldering multiple myeloma (SMM) in a diverse population
    Meeting Abstract

    Atrash, S.; Robinson, M.; Cassetta, K.; Varga, C.; Pineda-Roman, M.; Friend, R.; Paul, B.; Usmani, S.; Luong, V.; Voorhees, P.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Assessment of renal outcome following therapy in monoclonal immunoglobulin deposition disease: A retrospective study of 34 patients highlighting the need for consensus criteria
    Meeting Abstract

    Pianko, M. J.; Tiutan, T.; Derkach, A.; Jaffer-Sathick, I.; Rossi, A.; Salvatore, S.; Landau, H.; Lahoud, O.; Korde, N.; Mailankody, S.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • A first-in-human phase 1 study of oral LOXO-338, a selective BCL2 inhibitor, in patients with advanced hematologic malignancies (trial in progress)
    Meeting Abstract

    Kumar, S.; Kapoor, P.; Alencar, A.; Murthy, G. S. G.; Hoffmann, M.; Pagel, J.; Patel, V.; Pauff, J.; Zinzani, P. L.; Le Gouill, S.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save